ArticleCell and tissue banking2025
Wound healing by enhancing cell proliferation: a thermoreversible formulation containing raloxifene.
Article in Cell and tissue banking, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Situ Forming Poloxamer-Based Thermo-Sensitive Hydrogels for Ocular Application: A Focus on the Derivatives 407 and 188.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The challenge of ineffective wound healing, leading to chronic conditions necessitates the development of novel therapeutics strategies. Currently, a plethora of ailments have been researched and marketed globally to accelerate angiogenesis, re-epithelization, collagen synthesis, and proliferation. However, clinical translation remains challenging and requires rigorous pre- and post-clinical screening. Here, we have developed a formulation encapsulating Raloxifene, a repurposed drug, aimed to induce accelerated wound healing. Four different formulations (Forms 1, 2, 3, and 4) incorporating alginate, poloxamer 407 (P407), LiCl, and fetal bovine serum were prepared. Formulations were characterized by scanning electron microscopy, Fourier Transformation infrared spectroscopy, and rheology. In vitro assessments encompassing cell viability, cell migration, and drug release profile were conducted, subsequently, the in vivo wound healing potential was evaluated in Sprague Dawley (SD) rats. In results, we observed significant (p-value<0.05) wound healing by Form 3 at 14th due to up-regulation of TGFꞵ, Col-I and GSK3β genes. The histology results showed complete development of epidermis, endoderm and collagen fibers by Form 3, leading to complete healing. This formulation shows promise for clinical application in accelerated wound healing processes.
Indexed as
Identifiers
40272605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.